• Explore /
  • Poster
  • / Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor.

Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor.

Abstract Poster

Authors

null

Ashley P Wright

Dantari, Inc., Thousand Oaks, CA

Ashley P Wright , Jodi D Bradley , Timothy Hagerty , Emily A Wyatt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1081)

DOI

10.1200/JCO.2021.39.15_suppl.1081

Abstract #

1081

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

A biomarker-guided approach to combining PARP inhibitors with radiotherapy in pediatric solid tumors.

A biomarker-guided approach to combining PARP inhibitors with radiotherapy in pediatric solid tumors.

First Author: Anang Shelat

First Author: Do-Youn Oh

First Author: Sarina A. Piha-Paul

First Author: Katherine Foster